Design Therapeutics Inc

For the period ended Dec 31, 2023. Filed Mar 19, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 19, 2024

DSGN$10.65-1.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Balance Sheets as of December 31, 2023 and 2022

Balance Sheets

(in thousands, except share and par value data)

	December 31,	December 31,
	2023	2022
Assets
Current assets:
Cash and cash equivalents	$21,200	$26,500
Investment securities	260,598	303,887
Prepaid expenses and other current assets	2,786	4,732
Total current assets	284,584	335,119
Property and equipment, net	1,691	1,947
Right-of-use asset, related party	2,938	3,612
Other assets	430	459
Total assets	$289,643	$341,137
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$1,940	$3,025
Accrued expenses and other current liabilities (including related party amounts of $716 and $640, respectively)	7,682	7,751
Total current liabilities	9,622	10,776
Operating lease liability, net, related party	2,334	3,051
Total liabilities	11,956	13,827
Commitments and contingencies (See Note 11)
Stockholders' equity:
Common stock: $0.0001 par value; 200,000,000 shares authorized, 56,473,598 and 55,943,314 shares issued, and 56,473,598 and 55,895,596 shares outstanding at December 31, 2023 and 2022, respectively	6	6
Additional paid-in capital	455,245	441,424
Accumulated deficit	(177,626)	(110,764)
Accumulated other comprehensive loss	62	(3,356)
Total stockholders' equity	277,687	327,310
Total liabilities and stockholders' equity	$289,643	$341,137

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.